Abstract
We evaluated the effects Turkey Conversion Programme in Health in 2004 on drug market used for treatment of asthma.
We analyzed the data from IMS the programme following the drug market and the data from the Social Security Institution (SSI) for comparative studies.
In 2004 SSI paid nearly 4.0 billion Euro for drugs which increased to 8,5 billion (110%).Inhaler dust asthma drugs was 88.9 million and increased to 280.6 million (3.16 fold). Drug prescribed was 6.037.172 and increased to 20.848.085 boxes (3.45 fold).In the market of subgroup for inhaler dust asthma drugs distribution was; the rescue drugs 31.5%, combined drugs 17.7%, nebules 10.5%.The rates in 2009 were 20.2%, 29.6% and 18% respectively. Economically distribution was; 48.4% for combined drugs, 6.3% for nebules and 6.3% for rescue drugs.Rates for 2009 were 58.4%, 9.2% and 4.1%.The number of rescue drugs increased from 1.901.938 boxes to 4.220.664 (2.22 folds). The financial increase was 4.62 fold from 5.570.177 to 25.739.326.The number for nebules was 631.184 and increased to 3.762.806 (5.96 fold) the cost for them was 5.570.177 increased to 25.739.326 (4.62 fold).The combined drug subgroup the number of prescriptions were 1.066.486 increased to 6.178.315 (5.79 fold).The cost was 43.006.559 and increased to 163.814.343.
There has been an increase in the costs for inhaler drugs used for asthma treatment.Our analyses showed that this increase mostly caused by increase in the number of prescribed combined drugs. This increase we believe decreased the need for rescue drugs but had no effect on the nebules that has been used
- © 2011 ERS